A b s t r a c t
Cancer antigen 125 (CA 125) is a high-molecular-mass glycoprotein (>200 kd) and initially was recognized by monoclonal antibody OC125. The OC125 monoclonal antibody was generated by immunization of BALB/c mice with the OVCA43 cell line isolated from ascites fluid of a patient with serous papillary cystadenocarcinoma of the ovary. 1 CA 125 carries 2 major antigenic domains, and monoclonal antibodies against it can be classified as OC125-like or M11-like. 2 CA 125 contains 24% carbohydrate and is expressed normally in fetal coelomic epithelium, by epithelial ovarian tumors, normal and pathologic tissues of müllerian duct origin, and mesothelial cells. 3, 4 The CA 125 assay is useful for determining the prognosis of endometrial carcinoma, in evaluation of advanced endometriosis, and as an aid in monitoring the response to therapy for patients with epithelial ovarian cancer. 5 The assay is not useful for screening for ovarian cancer in asymptomatic women. 6 An immunoradiometric assay for CA 125 was first commercialized by Centocor (now Fujirebio Diagnostics, Malvern, PA). That assay used the OC125 monoclonal antibody for capture and tracer functions. To improve on the sensitivity and specificity of the first-generation assays, a double-determinant monoclonal antibodybased format was developed using 2 monoclonal antibodies with specificities against the antigenic domains OC125 and M11. The second-generation assays have been reported to show better agreement than the first-generation assays. [7] [8] [9] [10] [11] [12] [13] In the present study, 7 automated second-generation immunoassays for CA 125 were evaluated for detection limit, dilution linearity, imprecision, method comparison, and reference intervals.
Materials and Methods
The 7 assays that were evaluated were the Access 2 (Beckman Coulter, Brea, CA), ADVIA Centaur (Bayer Diagnostics, Tarrytown, NY), ARCHITECT i2000 (Abbott Diagnostics, Abbott Park, IL), AxSYM (Abbott), Elecsys 2010 (Roche Diagnostics, Indianapolis, IN), IMMULITE 2000 (Diagnostic Products, Los Angeles, CA), and VITROS ECi (Ortho Clinical Diagnostics, Raritan, NJ). All assays were performed in 1 laboratory according to the manufacturer's instructions.
The limit of detection of each method was determined by analyzing 10 replicates of the zero calibrator and 4 replicates of the lowest nonzero calibrator Dilution linearity was assessed by pooling 2 or 3 patient samples with similar high CA 125 concentrations for each method, making serial dilutions (1:2 to 1:32), and analyzing each sample in triplicate. The upper limits chosen were based on the analytic measurement range stated in each assay's package insert. For the Access 2 and Elecsys 2010 methods, the concentration of the high pool was approximately 5,000 U/mL (5,000 kU/L); for the ARCHITECT i2000 and VITROS ECi, the high pool was approximately 1,000 U/mL (1,000 kU/L); and for the ADVIA Centaur, AxSYM, and IMMULITE 2000 methods, the high pool was approximately 500 U/mL (500 kU/L). Whenever appropriate, the pooled patient samples were first diluted with the manufacturer's recommended diluent until they were within the analytic measurement range of each method.
For the Access 2, the patient sample with high CA 125 values was serially diluted with Diluent A (Beckman Coulter) to give final concentrations of 0.3%, 0.78%, 1.5%, 3.1%, 6.25%, 12.5%, 25%, 50%, and 100% (range of CA 125 concentrations, 23-5,087 U/mL [23-5,087 kU/L]). For the ADVIA Centaur, serial dilutions were made with MD1 diluent (Bayer Diagnostics) to give final concentrations of 1.5%, 3.1%, 6.25%, 12.5%, 25%, 50%, and 90% (range of CA 125 concentrations, 10-538 U/mL [10- Imprecision studies were performed by assaying Lyphocheck Tumor Marker Controls (Bio-Rad Laboratories, Hercules, CA) and the manufacturer's high control for each analyzer, analyzed in replicates of 2 per run. Two runs per day were conducted on each of 5 days with a minimum of 2 hours separating each run for the total of 20 replicates for each level of quality control material. Assay imprecision data were analyzed by using EP Evaluator Release 5 software.
Correlation studies were performed with 98 specimens from females between the ages of 14 and 87 years and with CA 125 concentrations from 0 to 1,000 U/mL (0-1,000 kU/L). The samples were tested according to the package insert instructions for each method. The samples with measured concentrations of more than the analytic measurement range for each method were rerun after dilution according to the manufacturers' instructions. The VITROS ECi was chosen as the comparison method because it correlated the best with all of the other methods. Passing-Bablok regression analysis was performed using Analyse-it + Clinical Laboratory, version 1.63 software (Analyse-It Software, Leeds, England).
Reference intervals were determined using samples from 120 apparently healthy women between 20 and 65 years of age who were not taking any prescription medications. One subject with the highest CA 125 concentration in this group was found to have ovarian cancer; therefore, her samples were excluded from further analysis. Statistical analysis was performed using EP Evaluator Release 5 software. The 97.5 percentile upper reference limit was determined using a transformed parametric approach. All studies using samples from human subjects were approved by the institutional review board of the University of Utah, Salt Lake City.
Results
The limit of detection ranged from 0.05 U/mL (0.05 kU/L) on the Access 2 to 1.45 U/mL (1.45 kU/L) on the AxSYM. The limit of detection was 0.30 U/mL (0.30 kU/L) for the ADVIA Centaur method, 0.35 U/mL (0.35 kU/L) for the ARCHITECT i2000 method, 0.09 U/mL (0.09 kU/L) for the Elecsys 2010 method, 0.10 U/mL (0.10 kU/L) for the IMMULITE 2000 method, and 0.06 U/mL (0.06 kU/L) for the VITROS ECi method. In all cases, the detection limit we measured was lower than the manufacturer's claim.
For dilution linearity studies, the maximum average deviation from target recovery was 10.9% for the Access 2 at 162 U/mL (162 kU/L), 3.7% for the ADVIA Centaur at 150 U/mL (150 kU/L), 8.2% for the ARCHITECT i2000 at 128 U/mL (128 kU/L), 7.7% for the AxSYM at 35 U/mL (35 kU/L), 10.7% for the Elecsys 2010 at 151 U/mL (151 kU/L), 18.2% for the IMMULITE 2000 at 52 U/mL (52 kU/L), and 4.1% for the VITROS ECi at 120 U/mL (120 kU/L). It is noteworthy that the upper limit of the analytic measurement range was 5,000 U/mL (5,000 kU/L) for the Access 2 and Elecsys 2010 methods, 1,000 U/mL (1,000 kU/L) for the ARCHITECT i2000 and VITROS ECi methods, 600 U/mL (600 kU/L) for the ADVIA Centaur method, 500 U/mL (500 kU/L) for the AxSYM method, and 400 U/mL (400 kU/L) for the IMMULITE 2000 method based on our studies with 1 lot of reagent. Approximately 0.5% of the CA 125 results generated in our laboratory are greater than 5,000 U/mL (5,000 kU/L), 3.2% are greater than 1,000 U/mL (1,000 kU/L), and 5.6% are greater than 500 U/mL (500 kU/L).
The imprecision of each assay was assessed by using commercial serum-based quality control materials. The coefficients of variation (CVs) for the low control (35 U/mL [35 kU/L]) were 1.3% to 8.3% within run, 0% to 3.1% between runs, and 2.0% to 8.3% total ❚Table 1❚. For the high control (114 U/mL [114 kU/L]), CVs were 1.4% to 4.3% within run, 0% to 3.2% between runs, and 1.8% to 6.3% total.
Results from method comparison studies with PassingBablok analysis are shown ❚Figure 1❚. Slopes ranged from 0.87 for the IMMULITE 2000 assay to 1.19 for the ARCHI-TECT i2000. Difference plots for the same data are shown ❚Figure 2❚. The mean differences ranged from -30 U/mL (-30 kU/L) for IMMULITE 2000 to 63 U/mL (63 kU/L) for the ARCHITECT i2000 method. The IMMULITE 2000 had 2 results that were lower than the VITROS ECi method by 250 U/mL (250 kU/L) or more ( Figure 2F ). The analytic concordance of each method with the comparison method for these samples is shown using the manufacturers' suggested upper reference limits ❚Table 2❚. Reference interval information obtained using samples from apparently healthy women is shown ❚Table 3❚. The median CA 125 concentration varied from 6.3 U/mL (6.3 kU/L) for the IMMULITE 2000 to 17.2 U/mL (17.2 kU/L) for the ELECSYS 2010 method.
Discussion
The detection limit of all 7 immunoassays was less than 1.5 U/mL (<1.5 kU/L) and was lower than manufacturers' claimed sensitivity. Linearity was acceptable for all methods, with recoveries within 10% of the target values except for the IMMULITE 2000 method, in which an 18.2% deviation from the target value was observed. The manufacturer's claimed analytic measurement range for the IMMULITE 2000 is up to 500 U/mL (500 kU/L), but our data for 1 lot of reagent demonstrated linearity only to 400 U/mL (400 kU/L). The imprecision of all automated assays was adequate, with total CVs of less than 8.3% even at CA 125 concentrations that were at or near a clinical decision threshold of 35 U/mL (35 kU/L). The results of the present study show that all 7 secondgeneration immunoassays are highly comparable to each other. The slope of IMMULITE 2000 compared with the VIT-ROS ECi was 0.87. The lower slope of the IMMULITE 2000 method relative to the comparison method could be due partly to a deviation from linearity with underrecovery at CA 125 concentrations between 400 and 500 U/mL (400-500 kU/L). However, results from reference interval studies also gave lower values with the IMMULITE 2000 assay, suggesting differences in calibration. The ARCHITECT i2000 had a slope of 1.19 relative to the VITROS ECi comparison method. Results from reference interval studies demonstrated higher values as well. Relatively small differences in calibration likely explain these regression and difference plot results. A previous report that examined 7 CA 125 immunoassays found slopes from regression analysis that ranged between 0.61 and 1.80. 13 Our results suggest that agreement among commercial methods has improved since that study was published. 
